A Multicenter, Randomized Phase III Study on Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma multiforme:–>

From clinicaltrials.gov:

INTRAGO II resembles a multicentric, prospective, randomized, 2-arm, open-label clinical phase III trial which tests if the median progression-free survival (PFS) of patients with newly diagnosed glioblastoma multiforme (GBM) can be improved by the addition of intraoperative radiotherapy (IORT) to standard radiochemotherapy.

More information

Development of a guiding device based on Raman spectroscopy for the accurate intraoperative identification of tumoral tissue during surgical resection of brain tumours 

In this clinical study, a probe  developed by the Reveal Surgical will be used in conjunction with a measuring device developed at the Laboratory of Radiological Optics (LRO) at Polytechnique Montreal to develop a new tool to help guide surgeons during brain tumour surgery.  

This tool is based on a technology called “Raman spectroscopy”, which uses light to retrieve information about the brain. The surgeon holds a stylus that shines a small beam of light on the brain, and by analyzing the light that comes back from the brain, the Raman device provides information about the composition of the brain tissue. This composition is different between normal and cancerous brain tissue. Eventually, these readings on the brain with the new Raman device could help the surgeon decide more easily which tissue to remove during surgical resection of brain tumours.